S&P 500   3,133.69 (+0.04%)
DOW   27,841.88 (-0.14%)
QQQ   204.43 (+0.26%)
AAPL   269.90 (+0.53%)
FB   201.23 (+0.18%)
MSFT   151.08 (-0.04%)
GOOGL   1,343.28 (+0.03%)
AMZN   1,740.04 (+0.05%)
NVDA   216.11 (+1.00%)
MU   48.79 (+2.80%)
BABA   203.57 (+1.56%)
GE   10.97 (-0.36%)
T   38.07 (+0.03%)
AMD   39.30 (-0.35%)
ACB   2.45 (-2.77%)
F   9.13 (+0.66%)
NFLX   297.66 (+1.55%)
DIS   147.00 (+0.62%)
S&P 500   3,133.69 (+0.04%)
DOW   27,841.88 (-0.14%)
QQQ   204.43 (+0.26%)
AAPL   269.90 (+0.53%)
FB   201.23 (+0.18%)
MSFT   151.08 (-0.04%)
GOOGL   1,343.28 (+0.03%)
AMZN   1,740.04 (+0.05%)
NVDA   216.11 (+1.00%)
MU   48.79 (+2.80%)
BABA   203.57 (+1.56%)
GE   10.97 (-0.36%)
T   38.07 (+0.03%)
AMD   39.30 (-0.35%)
ACB   2.45 (-2.77%)
F   9.13 (+0.66%)
NFLX   297.66 (+1.55%)
DIS   147.00 (+0.62%)
S&P 500   3,133.69 (+0.04%)
DOW   27,841.88 (-0.14%)
QQQ   204.43 (+0.26%)
AAPL   269.90 (+0.53%)
FB   201.23 (+0.18%)
MSFT   151.08 (-0.04%)
GOOGL   1,343.28 (+0.03%)
AMZN   1,740.04 (+0.05%)
NVDA   216.11 (+1.00%)
MU   48.79 (+2.80%)
BABA   203.57 (+1.56%)
GE   10.97 (-0.36%)
T   38.07 (+0.03%)
AMD   39.30 (-0.35%)
ACB   2.45 (-2.77%)
F   9.13 (+0.66%)
NFLX   297.66 (+1.55%)
DIS   147.00 (+0.62%)
S&P 500   3,133.69 (+0.04%)
DOW   27,841.88 (-0.14%)
QQQ   204.43 (+0.26%)
AAPL   269.90 (+0.53%)
FB   201.23 (+0.18%)
MSFT   151.08 (-0.04%)
GOOGL   1,343.28 (+0.03%)
AMZN   1,740.04 (+0.05%)
NVDA   216.11 (+1.00%)
MU   48.79 (+2.80%)
BABA   203.57 (+1.56%)
GE   10.97 (-0.36%)
T   38.07 (+0.03%)
AMD   39.30 (-0.35%)
ACB   2.45 (-2.77%)
F   9.13 (+0.66%)
NFLX   297.66 (+1.55%)
DIS   147.00 (+0.62%)
Log in

Audentes Therapeutics Price Target & Analyst Ratings (NASDAQ:BOLD)

$59.45
-0.06 (-0.10 %)
(As of 12/11/2019 01:48 PM ET)
Today's Range
$59.40
Now: $59.45
$59.68
50-Day Range
$25.50
MA: $32.81
$59.39
52-Week Range
$17.95
Now: $59.45
$59.51
Volume594,839 shs
Average Volume646,456 shs
Market Capitalization$2.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Analyst Ratings

Audentes Therapeutics (NASDAQ:BOLD) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
17 Wall Street analysts have issued ratings and price targets for Audentes Therapeutics in the last 12 months. Their average twelve-month price target is $48.36, suggesting that the stock has a possible downside of 18.66%. The high price target for BOLD is $60.00 and the low price target for BOLD is $10.00. There are currently 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.182.602.602.60
Ratings Breakdown: 0 Sell Rating(s)
14 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.36$40.99$42.49$39.99
Price Target Upside: 18.66% downside43.48% upside36.63% upside5.63% upside

Audentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00Low
12/4/2019Chardan CapitalReiterated RatingBuy ➝ Neutral$60.00Low
12/4/2019Leerink SwannDowngradeOutperform ➝ Hold$60.00Low
12/4/2019Svb LeerinkReiterated RatingOutperform ➝ Market PerformLow
12/3/2019Wells Fargo & CoLower Price TargetOutperform$20.00 ➝ $19.00N/A
12/3/2019Raymond JamesDowngradeOutperform ➝ Market PerformN/A
12/3/2019HC WainwrightDowngradeBuy ➝ Neutral$60.00N/A
12/3/2019MizuhoDowngradeBuy ➝ NeutralN/A
12/3/2019WedbushDowngradeOutperform ➝ Neutral$60.00N/A
12/3/2019CitigroupUpgradeSell ➝ Neutral$30.00 ➝ $60.00N/A
12/3/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$47.00 ➝ $60.00N/A
12/3/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$55.00 ➝ $60.00N/A
12/3/2019Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
12/3/2019GuggenheimDowngradeBuy ➝ NeutralN/A
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
8/7/2019William BlairReiterated RatingHoldHigh
1/31/2019CowenReiterated RatingBuyMedium
11/7/2018B. RileyBoost Price TargetSell$20.00 ➝ $21.00High
(Data available from 12/11/2017 forward)
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel